🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Avenue Therapeutics announced the last patient visit in its Phase 1b/2a clinical trial of #AJ201 for the treatment of #SpinalBulbarMuscularAtrophy (#SBMA), also known as #KennedysDisease. Topline data are expected to be reported mid-year 2024. $ATXI $FBIO bit.ly/4bkCari

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy $MBIO $FBIO bit.ly/3KKW4ju

Avenue Therapeutics will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference. The presentation will be available to registered attendees for on-demand viewing on Thursday, June 27, 2024 starting at 7:00 a.m. ET. $ATXI $FBIO bit.ly/3VF5CBQ

Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission $CKPT $FBIO bit.ly/4exHfOX

Checkpoint Therapeutics completed the resubmission of its BLA to the FDA for cosibelimab, its anti-PD-L1 antibody, as a potential new treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma. $CKPT $FBIO bit.ly/45Q3agn

GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research $CKPT $FBIO Learn more here: bit.ly/4bI1y9U

Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma; PDUFA goal date of December 28, 2024 set by FDA $CKPT $FBIO bit.ly/46m6Q9U

Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027 $FBIO bit.ly/3WmX175

Journey Medical Corporation to announce second quarter 2024 financial results on August 12, 2024. $DERM $FBIO For conference call details and more info: bit.ly/3WWByU8

Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights $ATXI $FBIO bit.ly/4cjirrK

Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates $CKPT $FBIO bit.ly/4cvony0

Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights $DERM $FBIO bit.ly/4co8dGx

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights $FBIO bit.ly/4co6ot9

Avenue Therapeutics to Participate in Upcoming Investor Conferences bit.ly/3Z4Ubqg

Checkpoint Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference $CKPT $FBIO bit.ly/4cTO9Mg

Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference $DERM $FBIO bit.ly/4cPG2QV

Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference $FBIO bit.ly/3Tf8rsK

Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference $FBIO $DERM bit.ly/3XATWSJ

Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024 $CKPT $FBIO bit.ly/3MO1H1y

Fortress Biotech to Participate in October 2024 Investor Conferences $FBIO bit.ly/3ZXLNcL